Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

Tidepool and Abbott’s new data integration will simplify data sharing by automating data upload to Tidepool for patients ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

Tidepool today announced a new data integration with Abbott for the company's FreeStyle Libre continuous glucose monitors ...

Abbott announced today that the FDA said users can wear the FreeStyle Libre 2 and 3 CGMs during common imaging procedures.

Abbott (NYSE: ABT) today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, ...

Many of us with loved ones living with diabetes want to see them thrive. We often think of ways we can ease some of their ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

Within medical devices, diabetes sales were up 15.8% led by FreeStyle Libre. Abbott expects its total 2024 revenue to rise 9.5% to 10% on an organic basis. The company saw its adjusted pre-tax ...

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. Tidepool ...